NOVO.B.DK

463.05

-1.05%↓

COLO.B.DK

694.4

-0.86%↓

ZEAL.DK

462.2

+0.7%↑

HLUNB.DK

31.9

+0.82%↑

AMBUB.DK

115.55

+1.14%↑

NOVO.B.DK

463.05

-1.05%↓

COLO.B.DK

694.4

-0.86%↓

ZEAL.DK

462.2

+0.7%↑

HLUNB.DK

31.9

+0.82%↑

AMBUB.DK

115.55

+1.14%↑

NOVO.B.DK

463.05

-1.05%↓

COLO.B.DK

694.4

-0.86%↓

ZEAL.DK

462.2

+0.7%↑

HLUNB.DK

31.9

+0.82%↑

AMBUB.DK

115.55

+1.14%↑

NOVO.B.DK

463.05

-1.05%↓

COLO.B.DK

694.4

-0.86%↓

ZEAL.DK

462.2

+0.7%↑

HLUNB.DK

31.9

+0.82%↑

AMBUB.DK

115.55

+1.14%↑

NOVO.B.DK

463.05

-1.05%↓

COLO.B.DK

694.4

-0.86%↓

ZEAL.DK

462.2

+0.7%↑

HLUNB.DK

31.9

+0.82%↑

AMBUB.DK

115.55

+1.14%↑

Search

Genmab A-S

Open

1,281.5 -0.08

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1259.5

Max

1292

Belangrijke statistieken

By Trading Economics

Inkomsten

2.1B

3.8B

Verkoop

901M

6.4B

K/W

Sectorgemiddelde

11.038

63.778

EPS

60.121

Winstmarge

59.696

Werknemers

2,682

EBITDA

-297M

1.8B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-1.49% downside

Dividenden

By Dow Jones

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.2B

85B

Vorige openingsprijs

1281.58

Vorige sluitingsprijs

1281.5

Genmab A-S Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2025, 15:16 UTC

Belangrijke Marktbewegers

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

3 apr 2024, 13:04 UTC

Acquisities, Fusies, Overnames

Correction to Genmab Article

3 apr 2024, 08:08 UTC

Acquisities, Fusies, Overnames

Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio

10 dec 2024, 07:05 UTC

Marktinformatie

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Vergelijking

Prijswijziging

Genmab A-S Prognose

Koersdoel

By TipRanks

-1.49% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 2,493.35 DKK  -1.49%

Hoogste 3,320 DKK

Laagste 308.417 DKK

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Genmab A-S - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

7 ratings

3

Buy

2

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.